Brief: Bioceltix Plans To Increase Capital To Partially Finance New Stem Cell Facility

Bioceltix SA

15/09/2025 07:39

Sept 15 (Reuters) - Bioceltix SA BCXP.WA:

SAID ON FRIDAY THAT IT PLANS TO INCREASE ITS CAPITAL THROUGH ISSUE OF NEW SHARES, REPRESENTING UP TO 8.51% OF INCREASED SHARE CAPITAL

THE COMPANY SIGNED AN INVESTMENT AGREEMENT WITH SHAREHOLDERS, ALTERNATIVE SOLUTION ASI AND KVARKO GROUP ASI, UNDER WHICH THEY WILL OFFER UP TO 457,785 OF EXISTING SHARES FOR SALE TO INVESTORS IN A PUBLIC OFFER

OBTAINED FUNDS WILL BE USED TO PURCHASE THE SAME NUMBER OF NEW ISSUE SHARES AT THE SAME PRICE PER SHARE AS THE ONE RECEIVED IN THE PUBLIC OFFER CONDUCTED UNDER THE ACCELERATED BOOK-BUILDING

UNDER THE AGREEMENT SHAREHOLDER ALTERNATIVE SOLUTION ASI CAN ALSO SELL AN ADDITIONAL 120,000 EXISTING SHARES WITHIN ABB, WITHOUT THE OBLIGATION TO TRANSFER FUNDS TO INCREASE THE COMPANY'S CAPITAL

THE INVESTMENT AGREEMENT ALSO INCLUDES THE INTENTION TO SET THE MINIMUM ISSUE PRICE AT 95 ZLOTYS

THE GENERAL MEETING OF SHAREHOLDERS WILL VOTE ON THE NEW ISSUE ON OCTOBER 9

PROCEEDS FROM CAPITAL INCREASE TO PARTIALLY FINANCE THE CONSTRUCTION AND LAUNCH OF A NEW STEM CELL FACILITY

THE NEW FACILITY WILL ENSURE THE PRODUCTION OF TARGET VOLUMES OF THE COMPANY'S MEDICINAL PRODUCTS INTENDED FOR INTERNATIONAL SALE IN THE PRODUCTION-LICENSING MODEL

ULTIMATELY, THE FUNDS OBTAINED WILL ENABLE THE COMMERCIALIZATION OF COMPANY'S PROJECTS: TWO INTENDED FOR DOGS – FOR OSTEOARTHRITIS AND ATOPIC DERMATITIS, AND THE THIRD INTENDED FOR HORSES SUFFERING FROM LAMENESS

Source text: https://shorturl.at/yHIzB
Further company coverage: BCXP.WA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))